OxMorA retweetledi
startups will be able to submit their project on the bio/acc website and i will try to implement some type of voting system for the projects with bio/acc coins, kind of like a DAO for biotech startups.
English
OxMorA
6.4K posts
OxMorA
@OxMorA_
🎲 Crypto gambler always rolling the dice | 🌕 To the moon or to the basement—either way, it's a ride 😎
Earth Katılım Mayıs 2021
81 Takip Edilen749 Takipçiler
OxMorA retweetledi
In the new bio/acc website, there will be a new manifesto section where people can sign! This will be for solana as the original manifesto is tailored towards eth users.
bio/acc!
CLP3exiqE8drZSzwhPas257cTh1evzq6nr7i1Xwvpump
English
OxMorA retweetledi
big news for bio/acc on solana.
we have creator fees + properly indexed on pumpfun now.
our cto is now proper!
bio/acc@bioacconsolana
We now have bio/acc properly indexed on pumpfun, and we are also receiving pumpfun creator rewards for the coin. This marks a very big step in our CTO journey of bio/acc. Trading fees will be used to provide funding to start up biotech projects, buyback supply to send to prominent bio/acc figures, and other stuff we as a community decide on. This is bio/acc on solana 🧬 CLP3exiqE8drZSzwhPas257cTh1evzq6nr7i1Xwvpump
English
OxMorA retweetledi
Biotech is only going up, and bio/acc will follow!
bio/acc is the movement of biotech, to make it programmable and infinitely faster.
we are the bio/acc community on solana. each breakthrough in biotech sends bio/acc even further.
lock in, nothing will stop us soon!
CLP3exiqE8drZSzwhPas257cTh1evzq6nr7i1Xwvpump
English
OxMorA retweetledi
We now have bio/acc properly indexed on pumpfun, and we are also receiving pumpfun creator rewards for the coin.
This marks a very big step in our CTO journey of bio/acc.
Trading fees will be used to provide funding to start up biotech projects, buyback supply to send to prominent bio/acc figures, and other stuff we as a community decide on.
This is bio/acc on solana 🧬
CLP3exiqE8drZSzwhPas257cTh1evzq6nr7i1Xwvpump
English
OxMorA retweetledi
OxMorA retweetledi
Biotech is quietly solving aging.
Not with injections.
Not with surgery.
But by telling your skin to rebuild itself.
A new biotech ingredient grown from plant cell cultures can stimulate the skin to produce its own structural molecules again.
Results from testing show major biological activation:
+103% hyaluronic acid
+28% collagen
+34% elastin
+23% glycosaminoglycans
These molecules form the structural foundation of youthful skin.
They hold water.
They maintain elasticity.
They keep the dermis firm.
As we age, production declines.
That decline is what creates wrinkles.
Traditional fillers try to solve this from the outside.
This biotech approach works from the inside.
Instead of injecting volume, it reactivates the skin’s biological machinery so the tissue rebuilds its own structure.
One signal molecule.
The skin restores the rest.
The production process is just as interesting.
Scientists grow plant cells in controlled laboratory cultures starting from a single seed. Those cells produce powerful bioactive compounds without farming, pesticides, or environmental damage.
This is what bio acceleration actually looks like.
Biology becoming programmable infrastructure.
Cosmetics becoming molecular engineering.
Skin becoming a regenerative system again.
Today the target is wrinkles.
Tomorrow it will be aging itself.
bio/acc is not a future concept.
It is already happening.
The Diet of Common Sense@DietCommon
Biotech Breakthrough: Filling Wrinkles From Within Biotechnology is revolutionizing skincare with a new, natural-origin ingredient that offers a needle-free, affordable alternative to expensive wrinkle injections. mykindofzen.com/biotech-fills-…
English
OxMorA retweetledi
Take a look at @m_goes_distance interview with @dranantmd on GLP-1.
bio/acc is everywhere!
Mgoes (bio/acc 🤖💉)@m_goes_distance
GLP-1s may be the first real human enhancement drug. I interviewed @dranantmd on why they could be a wedge into longevity, next-gen peptides, programable biology, and AI-driven human upgrades. 0:00 - Health → Human Enhancement? 5:37 - GLP-1s: The Real Novelty 8:23 - Next Gen Drugs, Peptides 13:29 - Un*ucking Regulation 22:50 - Health Influencers & Hype 29:23 - Social Media vs AI Discovery 35:46 - GLP1s = Prozac? 41:35 - Biotech Is The Answer 48:19 - AI Drug Discovery
English
OxMorA retweetledi
OxMorA retweetledi
OxMorA retweetledi
OxMorA retweetledi
bio/acc pushes further
Michael Okun@MichaelOkun
Japan just approved stem cells for Parkinson’s disease. How will it work? Stem cells are special cells that can develop into other types of cells. In this case they are turned into dopamine-producing brain cells designed to replace the cells lost in Parkinson’s disease. Sawamoto and colleagues described in a new paper in Nature one of the first phase I/II clinical trial using induced pluripotent stem cell derived dopaminergic progenitor cells transplanted into the brains of folks living w/ Parkinson’s disease. These cells are generated from iPS cells and implanted into the putamen where dopamine neurons normally function. Key Points: - Seven folks w/ Parkinson’s disease received bilateral transplantation of dopaminergic progenitor cells derived from iPS cells into the putamen and were followed for 24 months. - The transplanted cells survived, produced dopamine, and imaging revealed a roughly 44 percent increase in dopamine related activity in the putamen. - The procedure appeared safe w/ no tumors or graft overgrowth and several participants experienced improvements in motor scores on Parkinson’s rating scales. My take: Japan has a unique regulatory pathway for regenerative medicine that allows conditional approval once safety and early signals of benefit are demonstrated. For the therapy to advance in Japan data will be collected over the next 7 years. This paper represents an important milestone because it shows that lab grown dopamine cells can survive in the human brain and begin producing dopamine. The big questions ahead will be durability, patient selection, and whether the next 7 years of experience will confirm meaningful and sustained clinical benefit. Here are 5 points that resonated w/ me: 1- Parkinson’s disease is caused by the loss of dopamine producing neurons and this therapy attempts to replace those missing cells. 2- The transplanted cells are generated from induced pluripotent stem cells which are adult cells reprogrammed to behave like embryonic stem cells. 3- Brain imaging revealed new dopamine activity in the transplanted region suggesting the cells were functioning. 4- Safety remains the first hurdle and this trial showed no tumors or uncontrolled cell growth over two years of follow up. 5- The future will likely combine cell therapy w/ medications, rehabilitation, and possibly gene therapy to maximize benefit for folks living w/ Parkinson’s disease. Here is the Nature paper that set the stage for the recent approval. nature.com/articles/s4158… #parkinson @ParkinsonDotOrg @FixelInstitute
English
OxMorA retweetledi
There's a fruit fly walking around right now that was never born.
@eonsys just released a video where they took a real fly's connectome — the wiring diagram of its brain — and simulated it. Dropped it into a virtual body. It started walking. Grooming. Feeding. Doing what flies do.
Nobody taught it to walk. No training data, no gradient descent toward fly-like behavior. This is the opposite of how AI works. They rebuilt the mind from the inside, neuron by neuron, and behavior just... emerged. It's the first time a biological organism has been recreated not by modeling what it does, but by modeling what it is.
A human brain is 6 OOM more neurons. That's a scaling problem, something we've gotten very good at solving. So what happens when we have a working copy of the human mind?
English
OxMorA retweetledi
